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Heat-shock protein 90 associates with N-terminal
extended peptides and is required for direct
and indirect antigen presentation
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Center for Immunotherapy of Cancer and Infectious Diseases, Department of Immunology, University of Connecticut School of Medicine,
Farmington, CT 06030-1601
Communicated by Lloyd J. Old, Ludwig Institute for Cancer Research, New York, NY, December 3, 2007 (received for review September 17, 2007)
CD8 T cells recognize peptide fragments of endogenously synthe-
sized antigens of cancers or viruses, presented by MHC I molecules.
Such antigen presentation requires the generation of peptides in the
cytosol, their passage to the endoplasmic reticulum, loading of MHC
I with peptides, and transport of MHC I–peptide complexes to the cell
surface. Heat-shock protein (hsp) 90 is a cytosolic chaperone known
to associate with peptide and peptide precursors of MHC I epitopes.
We report here that treatment of cells with hsp90 inhibitors leads to
generation of ‘‘empty’’ MHC I caused by inhibited loading of MHC I
with peptides. Inhibition of hsp90 does not inhibit synthesis of MHC
I, nor does it affect the activity of proteasomes. Hsp90-inhibited cells,
such as proteasome-inhibited cells, are poor stimulators of T lympho-
cytes. The role of hsp90 in presentation of an ovalbumin epitope is
shown to be at a postproteasomal step: hsp90 associates with
N-terminally extended precursors of the SIINFEHL epitope, and such
peptides are depleted from hsp90 preparations in hsp90-inhibited
cells. Inhibition of hsp90 in the antigen donor cell compromises their
ability to cross-prime. Conversely, stressed cells expressing elevated
hsp90 levels show a heat-shock factor-dependent, enhanced ability to
cross-prime. These results demonstrate a substantial role for hsp90 in
chaperoning of antigenic peptides in direct and indirect presentation.
The introduction of a stress-inducible component in these pathways
has significant implications for their modulation during fever and
infection.
chaperones  cross-presentation  cross-priming  MHC I
CD8 T cells play a crucial role in the immune response tocancers and infections. These T cells recognize noncova-
lent complexes of MHC I and 8-aa peptides generated by
degradation of endogenous antigens. The degradation occurs
primarily in the cytosol, leading to generation of peptides that
enter the endoplasmic reticulum (ER) through the transporter
associated with antigen processing (TAP) (1). Within the ER,
the peptides are loaded onto MHC I and trimmed to size (2,
3), and theMHC I–2-microglobulin–peptide complex is trans-
ported to the cell surface. Of the three components of this
trimolecular complex, the peptide remains mysterious in terms
of the mechanisms of its journey from the point of its
generation to its tryst with the MHC I. Clearly, the peptides do
not diffuse freely; a biochemical analysis does not reveal the
presence of free peptides in cellular extracts (4, 5). The idea
that peptides are accompanied from the point of their gener-
ation to their entry into TAP and then within the ER by a
‘‘relay line’’ of chaperones was proposed early (6, 7). Biochem-
ical analyses have long shown the presence of hsp70 and
hsp90–peptide complexes in the cytosol and glycoprotein ofMr
96,000 (gp96) and calreticulin–peptide complexes in the ER
(8–15). Binder et al. (16) showed that antigenic peptides
chaperoned by heat-shock proteins (HSPs) were more efficient
by orders of magnitude than free peptides in being presented
by MHC I and that treatment of cells with deoxyspergualin, an
hsp70 inhibitor, leads to a reduced surface expression of folded
MHC I. Ishii et al. (11) noted that hsp70, hsp90, and gp96
isolated from murine leukemia cells were associated with a
precise Ld-restricted epitope and its precursors. Direct evi-
dence for an obligate association of peptides with chaperones
for antigen presentation came from Shastri and colleagues,
who developed an elegant method to detect precursors of a
modified ovalbumin (KOVAK)-derived antigenic peptide SI-
INFEHL (5). Kunisawa and Shastri (17, 18) showed that
association of SIINFEHL precursors with TRiC and hsp90 in
the cytosol was necessary for presentation of SIINFEHL by Kb.
Here, we explore mechanistically the involvement of hsp90 in
antigen presentation and cross-priming, and we show that (i) hsp90
plays a global role in direct presentation; (ii) this role is specific to
chaperoning of peptides by hsp90 and does not affect synthesis of
MHC I or the activity of proteasomes; (iii) hsp90 is involved
postproteasomally in chaperoning of endogenously generated N-
terminally extended peptides; and (iv) hsp90 plays a significant role
in cross-priming.
Results
Hsp90 Inhibitors Reduce Expression of Folded Cell Surface MHC I.
Stable cell surface expression of MHC I requires it to be peptide-
loaded. We have treated cultured murine cells with radicicol,
geldanamycin, or a geldanamycin derivative, 17-AAG, all specific
inhibitors of hsp90 that block its N-terminal ATP/ADP-binding
domain. Expression of surface-folded MHC I on untreated and
inhibitor-treated cells was assessed by staining with conformation-
specific antibodies against the appropriateMHC I. The cell line 4T1
(H-2d) was treated for 12 hwith titrated concentrations of inhibitors
indicated or DMSO as a control and surface-stained with the
antibody 30-5-7S specific for folded H-2Ld (19), or as a negative
control, with an antibody to the integralmembrane proteinMAC-3.
Expression of folded H-2Ld is significantly diminished in radicicol-
(46% reduction), geldanamycin- (59% reduction), or 17-AAG-
(48% reduction) treated cells compared with untreated cells (Fig.
1A). Treatment with either inhibitor had no effect on expression of
MAC-3. Surface expression of other control proteins CD71 and
ICAM-1 showed no inhibition (data not shown). Treatment of the
T antigen-transformed line SVB6 (H-2b) with radicicol or 17-AAG
followed by staining for folded Kb using the antibody Y3 showed a
reduction in expression of Kb but not control proteins MAC-3 and
ICAM1 [supporting information (SI) Fig. 6]. Similar data were
obtained with Ld, Dd, Kb, and Db (data not shown). The effect of
radicicol was shown to be time-dependent (SI Fig. 7).
Tyrosine kinases constitute a substantial proportion of the many
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client proteins of hsp90 (20). The possibility that the effects of hsp90
inhibitors resulted fromdownstream effects on tyrosine kinases was
considered. 4T1 cells were exposed to titrated quantities of the
potent tyrosine kinase inhibitor SU11652 (21) in parallel with
radicicol, and expression of folded Ld wasmonitored. Fig. 1B shows
that SU11652 had no effect on surface expression of folded Ld,
whereas radicicol did.
The ability of untreated and radicicol-treated cells to stimulate T
cells was tested. SVB6 cells that express the SV40 large T antigen
stimulate the antigen-specific CTL cloneK11 (22) to secrete IFN-.
K11 recognizes the T antigen epitope I (amino acids 206–215,
SAINNYAQKL) presented by SVB6; this epitope is deleted in the
T antigen-transformed cell line K-1, 4, 5. Untreated SVB6 cells,
cells treated with radicicol, and as a positive control, cells treated
with the proteasome inhibitor lactacystin were incubated for 20 h
withK11T cells, and the culture supernatantwas assayed for IFN-.
As seen in Fig. 1C, untreated SVB6 cells were able to stimulate K11
cells robustly, whereas the K-1, 4, 5 cells lacking a proper epitope
were unable to do so. Cells treated with lactacystin showed a
significantly diminished ability to stimulate K11 cells, as did the
radicicol-treated cells. Thus, inhibition of hsp90 diminishes the
antigen presenting capacity of cells to a level comparable with the
effects of proteasome inhibition.
Inhibition of Hsp90 Affects Charging of MHC I with Peptides. Un-
treated or radicicol- (10 M or 20 M) treated EL4 cells were
labeled with [35S]methionine for 3 h, and cell lysates were immu-
noprecipitated with the antibody K44 (23), which recognizes a
monomorphic epitope on all murine MHC I, or with Y3, which
recognizes peptide-loaded Kb (24). The immunoprecipitate was
resolved by SDS/PAGE and autoradiographed. In parallel, the
surface expression of folded Kb and Db was analyzed by FACS (as
in Fig. 1). The results of the surface staining were consistent with
the data shown in Fig. 1, such that radicicol-treated cells had a
significantly reduced expression of foldedMHC I (data not shown).
Immunoprecipitation experiments demonstrated (Fig. 2A) that
treatment of cells with radicicol (at each concentration) resulted in
a slight increase of K44-precipitated MHC I. However, treatment
with radicicol resulted in reduced immunoprecipitation of Y3-
reactive Kb. The bands in the gel were quantified in arbitrary units;
cells treated with radicicol (10 or 20 M) contained 142% and
132%, respectively, of theK44-precipitatedmaterial comparedwith
the untreated control. In contrast, cells treated with radicicol (10 or
20 M) contained 92% and 57%, respectively, of the Y3-
precipitated material compared with the untreated control (Fig.
2B). The ratio of Y3- to K44-precipitatedMHC I was calculated as
an index of peptide-loaded Kb, assigning as 1 the ratio of the two
values in untreated cells: treatment with radicicol led to a titrated
decrease (64.7% with 10 M radicicol and 43.1% with 20 M
radicicol) in peptide-loaded Kb (Fig. 2B), although synthesis of
MHC I is unaffected. Analysis of total synthesized proteins in
radicicol-treated cells showed no influence of radicicol on protein
synthesis (data not shown).
As another approach to measure empty MHC I, the ability of
exogenous peptides to ‘‘rescue’’ the surface expression of MHC I
was tested (25). SVB6 cells were treated with radicicol, lactacystin,
or control for 12 h. Each group was incubated in the presence or
absence of the Db T antigen epitope II peptide (CKGVNKEYL) at
1 M, and all cells were stained with the B22-249.R1 antibody
specific for folded Db. Untreated cells show a modest 1.3-fold
increase in folded Db upon pulsing with the exogenous peptide
CKGVNKEYL (Fig. 2C), consistent with a proportion of MHC I
on the surface being empty. Lactacystin- or radicicol-treated cells
show lower levels of Db than untreated cells, as in Fig. 1. However,
lactacystin-treated and peptide-pulsed cells show a significantly
higher increment (1.7-fold) in Db staining than lactacystin-treated
unpulsed cells, as expected from the fact that lactacystin-treated
cells have fewer peptides and more empty Db capable of being
rescued. Similarly, radicicol-treated and peptide-pulsed cells show
an even higher increment (1.9-fold) in Db staining than lactacystin-
treated unpulsed cells. Experiments for folded Ld with antibody
30-5-7S showed similar results (Fig. 2D): the ratio of folded Ld
between peptide-pulsed and unpulsed cells in untreated, lactacys-
tin-treated, and radicicol-treated cells was 1.3, 1.5, and 1.9,
respectively.
A similar experiment was carried out quantifying MHC I–pep-
tide complexes viaT cell stimulation (Fig. 2E).As a positive control,
the ratio of IFN- release between peptide-pulsed and unpulsed
cells in case of K-1, 4, 5 cells that lack epitope I was an enormous
214-fold. Untreated, or lactacystin-treated or radicicol-treated
SVB6 cells were unpulsed or pulsed with T antigen epitope I
(SAINNYAQKL) and were used to stimulate K11 cells. The ratio
of IFN- release between peptide-pulsed and unpulsed cells in
Fig. 1. Inhibition of hsp90 results in decreased levels
of foldedMHCclass I. (A) 4T1 cellswere treated for 12h
with the indicated inhibitor: 30 M radicicol (Left), 25
M geldanamycin (Center), 50 M 17-AAG (Right), or
with DMSO as a control. Cells were stained with an
antibody specific for conformational Ld (Upper) or for
MAC-3 (Lower) or isotype control antibodies. Staining
of inhibitor-treated cells (bold gray) is compared with
control cells (bold black) and isotype control stained
cells (thin black). (B) 4T1 cells were treated for 12 h
with titrated doses of SU11652, a tyrosine kinase in-
hibitor, or radicicol and then stained with antibody
specific for conformational Ld or an isotype control
antibody. Results are plotted as percentage surface Ld.
Error bars represent the standard deviation of tripli-
cate samples for a single experiment. (C) T antigen-
expressing SVB6 cells were treated with the indicated
doses of lactacystin, radicicol, or a vehicle control for
12 h. The T antigen epitope I-deficient K-1, 4, 5 cells
were used as a negative control. Treated cells were
added as stimulators of K11 cells (a T antigen epitope
I-specific T cell clone) for 20 h, and supernatant was
assayed for IFN-. Results of three independent exper-
iments (each performed in duplicate) are plotted,with
error bars representing the standard deviation be-
tween averages of two experiments.
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untreated, lactacystin-treated, and radicicol-treated cells was 8-fold,
23-fold, and 32-fold, respectively. Thus, inhibition of hsp90 leads to
an increased proportion of empty MHC I, comparable with or
greater than that observed with proteasome inhibition.
Inhibition of Hsp90 Is Not a Preproteasomal or a Proteasomal Step.
Charging of MHC I with peptides involves triaging of proteins for
degradation or refolding with the help of hsp90/hsp70 and their
co-chaperones (26), ubiquitination of proteins, generation of pep-
tides by proteasomes, and postproteasomal transport of peptides.
We sought to determine systematically which of these step(s) is
inhibited by inhibition of hsp90.
Inhibition of hsp90, such as by radicicol, inhibits refolding of
client proteins and sends more molecules to degradation by pro-
teasomes. We sought to test whether KOVAK is a client protein of
hsp90. If it were to be one, inhibition of hsp90 would lead to a more
rapid degradation of KOVAK. The protein kinase Akt (27) is a
known client protein of hsp90 and was used as a positive control.
PIK23 cells that express Akt and a GFP-KOVAK fusion protein
(seeMaterials and Methods) were labeled with [35S]methionine for
1 h, and the pulse was chased for 2, 4, and 8 h, followed by
immunoprecipitation of Akt and GFP-KOVAK. The precipitates
were resolved on SDS/PAGE, autoradiographed, and quantitated
(Fig. 3A). The results show that degradation of Akt is significantly
enhanced by inhibition of hsp90, whereas degradation of GFP-
KOVAK is unaffected under the same conditions. Thus, GFP-
KOVAK is not a client protein of hsp90, and inhibition of hsp90 has
no influence on its degradation. Next, the influence of radicicol on
ubiquitination was tested. 4T1 cells were treated with titrated doses
of the lactacystin (as a control) or radicicol for 12 h and evaluated
for accumulation of ubiquitinated proteins by immunoblotting of
cell lysates with anti-ubiquitin antibody (Fig. 3B). Although lacta-
cystin-treated cells show a massive accumulation of ubiquitinated
proteins in a dose-dependent manner, radicicol-treated cells show
a very modest accumulation and certainly no inhibition of ubiq-
uitination. Modest enhancement in the quantity of ubiquitinated
proteins by inhibition of hsp90 has been reported (28). Our
observations in Fig. 3B indicate that inhibition of hsp90 is not
influencing ubiquitination of proteins in a manner that may explain
its activity of inhibiting charging of MHC I with peptides.
The possibility that radicicol inhibits proteasomes was investi-
gated. The reporter construct pZsProsensor-1 (Clontech) encodes
a form of GFP with a murine ornithine decarboxylase domain that
targets the GFP for rapid degradation by the proteasome, without
ubiquitination. In cells with normal proteasome function, the
turnover of this GFP is too rapid for GFP to accumulate; thus, GFP
is detectable in these cells only if proteasomes are inhibited. A
stable clone of 4T1 cells expressing the plasmid (4T1-proSensor-
76B) was isolated and treated with titrated concentrations of
lactacystin (as a positive control) or radicicol for 12 h, and cells were
evaluated for expression ofGFP.Cells treatedwith lactacystin show
a titratable increase in GFP accumulation; in contrast, radicicol-
treated 4T1-proSensor-76B cells show no accumulation of GFP at
any dose tested (Fig. 3C). Thus, radicicol does not inhibit protea-
some activity.
Radicicol Inhibits Association of Hsp90 with N-Terminal Extended
Precursors. Considering that inhibition of hsp90 had no preprotea-
somal consequence, we investigated whether inhibition of hsp90
was influencing association of peptides with hsp90. Untreated or
radicicol-treated PIK23 cells were used to isolate hsp90 to homo-
geneity, and associated peptides were eluted as described (18, 29).
These peptides were used undigested, or they were treated with
trypsin to release any N-terminal extensions or with trypsin 
carboxypeptidase B (18) to release N- and C-terminal extensions
(Fig. 4A). Each of these peptide mixtures was pulsed onto L-Kb
cells, which were used to stimulate B3Z cells as described in
Materials and Methods (30). The results (Fig. 4B) show that un-
stimulatedB3Zhaveminimal activity, whereasB3Z cells stimulated
with the precise SIINFEHL epitope are powerfully stimulated. The
syntheticN- andC-terminal extendedprecursor of SIINFEHL in an
undigested form has no activity. Peptides eluted from hsp90 from
untreated PIK23 cells show significant stimulation of B3Z, and this
stimulation is enhanced further by digestion of peptides with
trypsin, indicating N-terminal extended precursors. Further diges-
tion of these peptides with carboxypeptidase B shows no further
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Fig. 2. Inhibition of hsp90 results in appearance of empty surfaceMHC I. (A)
EL4 cells were treated with the indicated dose of radicicol or DMSO for 12 h.
Cells were metabolically labeled with 35S for 3 h and lysed for immunopre-
cipitation with Y3 (specific for conformational H-2Kb) or K44 (recognizing
total mouse MHC I). An autoradiograph representative of two independent
experiments is shown. (B) The intensity of the Y3 (conformation-dependent)
or K44 (conformation-independent) immunoprecipitated MHC class I bands
from autoradiograph (A) was quantitated in arbitrary units (Top andMiddle).
The ratio the intensity of Y3 (conformation-dependent H-2Kb) to K44 (total
conformation-independentMHC I) was calculated in arbitrary units (Bottom).
The reduction in the Y3/K44 ratio seen in presence of 10 M radicicol is
statistically significant (P 0.008, two-tailed test). (C) SVB6 cells were treated
with 10 M lactacystin, 10 M radicicol, or DMSO for 12 h in the presence or
absence of the Db-restricted T antigen epitope II peptide (CKGVNKEYL). Cells
were stainedwith a Db conformation-specific antibody or isotype control and
analyzed as in Fig. 1B. (D) 4T1 cells were treatedwith 20M lactacystin, 30M
radicicol, or DMSO for 12 h in the presence or absence of the Ld-restricted
LCMV-NP peptide (RPQASGVYM). Cells were stained and analyzed as in Fig.
1B. (E) T antigen-expressing SVB6 cells were treated with the indicated doses
of lactacystin, radicicol, or a vehicle for 12 h in the presence or absence of the
T antigen epitope I peptide (SAINNYAQKL). The T antigen epitope I-deficient
K-1, 4, 5 cell line was used as a negative control. Treated cells were added as
stimulators of K11 cells (a T antigen epitope I-specific T cell clone) for 20 h, and
supernatant was assayed for IFN-. Results of three independent experiments
(each in duplicate) are plotted, with error bars representing the standard
deviation between the averages of duplicate samples.
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enhancement of stimulation, indicating that the mixture does not
contain C-terminal extended precursors. This pattern of stimula-
tion indicates that hsp90 from uninhibited PIK23 cells is associated
with SIINFEHL and its N-terminal extended precursors. Interest-
ingly, peptides eluted from hsp90 (undigested or digested) from
radicicol-treated PIK23 cells did not elicit any B3Z-stimulating
activity. Because proteasome activity is essential for generation of
peptides with the precise C terminus, our observations indicate that
radicicol inhibits association of hsp90 with peptides generated by
proteasomes and that this association is required for further trans-
port of peptides in the antigen presentation pathway.
Hsp90 Is Required for Cross-Priming of Cellular Antigen. Previous
studies have suggested that HSP-chaperoned peptides generated in
an antigen-expressing cell can act as the substrate for transfer to
antigen-presenting cells (APCs) during cross-priming (31, 32) and
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somal or proteasomal steps. (A) PIK23 cells were treated
with 10 M radicicol or DMSO for 7 h. Cells were met-
abolically labeled with 35S for 1 h and chased for time
points as indicated. Cells were lysed for immunoprecipi-
tation with anti-Akt (Left) or anti-GFP (Right) antibody.
Immunoprecipitated material was resolved by SDS/
PAGE and autoradiographed. The band intensity was
measured and plotted taking the initial time point (0 h)
as 100%. (B) 4T1 cells were treated with the indicated
doses of lactacystin, radicicol, or DMSO for 12 h and
lysed, resolved by SDS/PAGE, and immunoblotted for
ubiquitin. (C) 4T1-proSensor-76B, a clone stably express-
ing the pZsProSensor-1, was treated with the indicated
doses of lactacystin or radicicol for 12 h andanalyzed for
expression of GFP by FACS. Error bars in C represent
standard deviation of a single experiment performed in
triplicate. Results are representative of three indepen-
dent experiments.
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indeed may be necessary and sufficient for cross-priming (14); a
requirement for hsp90 in cross-priming of antigen from intact cells
has been hinted but not tested rigorously (33). The role of hsp90 in
cross-priming was tested by using radicicol and geldanamycin. 4T1
cells of the d haplotype, untreated or treated with radicicol or
geldanamycin, were electroporated with ovalbumin (OVA) and
used to immunize C57BL/6 mice of the b haplotype, which had
received OT-I cells. Expansion of the OT-I population was the
endpoint for cross-priming. As seen in Fig. 5A andB, immunization
with OVA-containing uninhibited 4T1 cells led to a significant and
vigorous expansion of OT-I cells; however, pretreatment of 4T1
cells with radicicol (Fig. 5A) or geldanamycin (Fig. 5B), caused a
significant, dose-dependent, and near complete inhibition of cross-
priming (respectively, P  0.0075, P  0.0073 at highest doses).
Inhibition of hsp90 did not affect the OVA content of the immu-
nizing cells at any concentration of inhibitor (see Fig. 5 A and B,
Insets).
To discriminate between specific effects of hsp90 in peptide
trafficking from nonspecific effects, 4T1-OVA cells were treated
with SU11652 instead of radicicol or geldanamycin and used for
immunization and measurement as in Fig. 5 A and B. Treatment
with SU11652 had no influence on cross-priming (Fig. 5C) or on
OVA content in the immunizing cells (Fig. 5C, Inset). To test
further for nonspecific effects, the sequence of the introduction of
OVA and treatment with radicicol was reversed before immuni-
zation of OT-I recipients. Reversal of order did not lead to
abrogation of cross-priming (Fig. 5D), indicating that the deficit in
cross-priming elicited by treatment with radicicol was specific to
some aspect of hsp90–OVA interaction. We considered the pos-
sibility that radicicol-treated 4T1 cells are toxic to the host APCs,
thus causing inhibition of cross-priming. Untreated or radicicol-
treated 4T1 cells were electroporated with OVA; and, as seen in
Fig. 5A, 4T1-OVA cells treated with radicicol are compromised in
their ability to cross-prime. If radicicol-treated 4T1-OVA cells were
toxic to cross-priming APCs, then they should abrogate cross-
priming of antigen from untreated 4T1-OVA cells in a dominant
fashion. Thus, we immunized OT-I recipient mice with titrated
mixtures of untreated and radicicol-treated 4T1-OVA cells, as
indicated in Fig. 5E. It is observed that upon immunization with
mixtures of radicicol-treated and untreated cells (in any ratio), the
inhibition of cross-priming is never the dominant phenotype.
The possibility that heat-shocked cells, which express higher
levels of most HSPs including hsp90, show enhanced cross-priming,
was tested. OT-I recipient mice were immunized with OVA-
electroporated or mock-electroporated cells that were or were not
heat-shocked at 42°C, and expansion of OT-I cells was monitored.
OVA-electroporated heat-shocked cells were significantly better
agents of cross-priming than corresponding non-heat-shocked cells
(SI Fig. 8A, P  0.01). Cells not containing OVA showed no
cross-priming activity. Treatment of heat-shocked cells with
KNK437, an agent that inhibits trimerization of the heat shock
factor (34), inhibited the heat shock-enhanced cross-priming
(SI Fig. 8B).
Discussion
A peptide-chaperoning property was attributed to hsp90 family
members in the early 1990s as a possible explanation for the specific
immunogenicity of tumor-derived HSP preparations (see refs. 6
and 7). Our results here support that explanation. Our results are
threefold. First, we show that sequestration of hsp90 leads to a
specific inhibition of loading of a variety of MHC I alleles with
cognate peptides and consequent abrogation of expression of
folded MHC I. Inhibition of hsp90 does not affect generation of
peptides or MHC I synthesis, but only MHC I loading. Second, our
results show that hsp90 associates with N-terminal extended pep-
tides; this observation places the role of hsp90 in direct presentation
specifically at a postproteasomal step, as envisaged by us (7). This
result differs from that obtained from Kunisawa and Shastri (18),
who noted that hsp90 was associated with N- and C-terminal
extended peptides. This discrepancy may arise from the fact that
Kunisawa and Shastri used immunoprecipitated hsp90 that may
include, adventitiously, hsp90-associated large KOVAK fragments,
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Fig. 5. Inhibition of Hsp90 inhibits cross-priming. (A) 4T1 cells were treated with the indicated doses of radicicol or DMSO for 6 h and electroporated with
purified, LPS-free, soluble OVA protein. Cells werewashed and irradiatedwith 7,500 Gray before being used to immunize OT-I recipients. Expansion of OT-I cells
in the draining lymph nodes was quantified and plotted as the percentage of the total CD8 population. (Inset) At the time of immunization, a portion of each
immunizing population was analyzed by immunoblotting for OVA. (B) 4T1 cells were treated with the indicated doses of 17-AAG or DMSO as a control for 6 h
and used for immunization as in A. (C) 4T1 cells were treated with the indicated doses of SU11652 or DMSO as a control for 6 h and used for immunization and
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ratios with untreated cells and used for immunization and analysis as in A.
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including the whole protein. In the studies here, we used instead
biochemically homogeneous preparations of hsp90 (see Fig. 4B,
Inset). Third, we present evidence for a role for hsp90 in cross-
priming, as envisaged by us on theoretical grounds (7). Inhibition
of hsp90 in the antigen donor cell inhibits cross-priming, whereas
heat shock conditions enhance cross-priming. Clearly, complexes of
any of the chaperones (gp96, hsp70, calreticulin) with peptides can
mediate cross-priming (14). However, the present data suggest that
association of hsp90 with peptides is upstream of association of
other chaperones with peptides, such that blocking hsp90 inhibits
the association of all other chaperones with peptides.
These observations firmly place the chaperoning of peptides by
hsp90 in direct and indirect antigen presentation and set the stage
for a closer scrutiny of the trafficking of peptides in the two
pathways. The introduction of a stress-inducible component in the
two antigen presentation pathways has significant implications for
of modulation of these pathways during fever and infection.
Materials and Methods
Cells, Antibodies, Peptides, and Chemicals. 4T1 (H-2d), EL4 (H-2b), andP815 (H-2d)
cells were purchased from American Type Culture Collection (ATCC). PIK23 cells
are P815 cells stably transfected with a gene encoding a fused GFP-KOVAK
protein, under an ecdysone-inducible promoter. The T antigen-transformed cell
line SVB6 (H-2b), K-1, 4, 5 cells, and K11 cells (a T antigen epitope I-specific T cell
clone)wereprovidedby Satvir Tevethia andToddSchell (both fromPennsylvania
StateUniversity, Hershey, PA). L-Kb cells (used asAPCs) andB3Z T cell hybridomas
were provided by David Williams (University of California, Berkeley, CA) and
Nilabh Shastri (University of Toronto, Toronto, ON, Canada). Conformational
specific antibodies for H-2Ld (30-5-7S; Cedar Lane), H-2Db (B22-249.R1; Cedar
Lane),H-2Dd (34-5-8S; BDPharMingen),H-2Kb (purified fromY3hybridoma from
ATCC) were used according to the manufacturers’ instructions. ICAM-1 (3E2; BD
PharMingen),Mac-3 (M3/84; ebiosciences), K44 (23), ubiquitin (Calbiochem),GFP
(Calbiochem), and Akt (Cell Signaling) were also used. H-2Ld-restricted epitope
from the LCMV-NP (118–126; RPQASGVYM), H-2Db-restricted T antigen epitope
I (206–215; SAINNYAQKL), epitope II (223–231; CKGVNKEYL), SHL8 (SIINFEHL),
and18-mer SHL8 (LEQLKSIINFEHLKEWTS)were synthesizedbyGenemedSynthe-
sis and were 95% pure. Lactacystin, 17-AAG, AdaAhx3L3VS, epoxomicin, and
SU11652 were purchased from Calbiochem. All chemicals were purchased from
Sigma unless otherwise specified.
Mice. C57BL/6 mice were purchased from the Jackson Laboratory. OT-I T cell
receptor transgenic RAG2/ (Taconic) mice were used to isolate TcR transgenic
cells. All animalworkwas approved by the Center for Laboratory Animal Care of
our school.
Purification of Hsp90 and Extraction of Chaperoned Peptides.Hsp90waspurified
as described in ref. 29. PIK23 (2  108) cells were Dounce-homogenized in
hypotonic buffer, and supernatantwas collected after a 100,000 g centrifuga-
tion. The bufferwas exchanged to phosphate buffer (20mMsodiumphosphate,
pH 7.4, 1 mM EDTA, with 200mMNaCl), and the sample was applied to aMono
Q (Amersham Biosciences) column. Bound proteins were eluted by a linear salt
gradient 200–600mMsodiumchloride. Hsp90 (2mg) eluted infive fractions at
500mMNaCl. These fractionswerepooledandboiled in10%formicacid for10
min. Eluted peptideswere lyophilized and desaltedwith a C18 column (Gracevy-
dac). Peptideswere lyophilized andused in B3Z cell activation assay (described in
SI Methods).
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